ALPG and familial pancreatic carcinoma: The abnormal expression of alkaline phosphatase placental-like 2 (ALPPL2) in pancreatic cancer cells makes ALPPL2 a putative biomarker for the development of targeted therapy for pancreatic cancer [129].